- Home
- SCNI vs BDRX Comparison
SCNI vs BDRX Comparison
Compare SCNI & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNI | BDRX |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.0M |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SCNI | BDRX |
|---|---|---|
| Price | $0.57 | $4.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.3M | 200.5K |
| Earning Date | 05-11-2026 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.60 |
| 52 Week High | $6.18 | $11.88 |
Technical Indicators
Market Signals| Indicator | SCNI | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.38 | 64.68 |
| Support Level | $0.54 | $3.79 |
| Resistance Level | $1.02 | $4.39 |
| Average True Range (ATR) | 0.11 | 0.38 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 16.92 | 65.22 |
Price Performance
Historical ComparisonAbout SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.